|
|
|
- Norwegian Pharmaceutical company founded in 1993
- Main office in Oslo
- Develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets
- The photodynamic technology combine a drug, known as a photosensitiser, with a light source that activates the photosensitiser
- Has three products with marketing authorisations:
o Metvix®, for the treatment of basal cell carcinoma (skin cancer), actinic keratosis
(pre-cancerous skin lesions) and Bowen’s disease
o Aktilite® CL 16 and CL 128, lamps that are intended for use in PDT (Photodynamic
therapy) in combination with Metvix®
o Hexvix®, for the detection of bladder cancer
- Operate in Denmark, Finland, Norway and Sweden
- Cooperates with two marketing partners for the global market:
o Galderma, a leading dermatology company (licensed Metvix® and Aktilite® from
Photocure
in December 2001)
o GE Healthcare, a leader in imaging (licensed Hexvix® from Photocure in January
2006)
- Photocure s also developing photochemical internalisation (PCI) which is a technology for light-directed drug delivery
o PCI Biotech AS, a subsidiary of Photocure, was established on 2000 to ensure an
optimal development of the PCI technology
- See financial figures
|
|
|
|